{"prompt": "['Protocol 036 (Nishijima, Kuppermann)', 'Page 7 of 74', '8 Data and Safety Monitoring Plan', '55', '8.1 Data Safety Monitoring Board (DSMB)', '55', '8.2 Frequency of Interim Analysis', '56', '8.3 Conflict of Interest', '56', '8.4 Adverse Event Reporting', '57', '8.4.1', 'Definitions, Relatedness, Severity and Expectedness', '57', '8.4.2', 'Time Period for Adverse Events', '59', '8.4.3', 'Data Collection Procedures for Adverse Events', '59', '8.4.4', 'Unanticipated Problems (UP)', '60', '8.4.5', 'Monitoring Serious Adverse Events', '60', '8.4.6', 'Follow-up of Serious, Unexpected and Related Adverse Events', '61', '9 Study Training', '61', '9.1 Study Training', '61', '9.2 PECARN Network Involvement', '62', '10 Regulatory Issues', '63', '10.1 Food and Drug Administration', '63', '10.2 Health Insurance Portability and Accountability Act', '63', '10.3 Inclusion of Women and Minorities', '63', '10.4 ClinicalTrials.gov Requirements', '63', '10.5 Retention of Records', '64', 'Bibliography', '64', 'List of Figures', '1', 'Schema of Study Objectives', '10', '2', 'Flow diagram of blood draws for biomarker testing and TXA levels', '20', '3', 'TEG parameters', '21', '4', 'Schedule of Evaluations', '23', '5', 'Plasma concentrations of TXA by dosing (Adapted from Koster et al.47).', '27', '6', 'Weight-Based Dosing for All Arms', '31', '7', 'Weight-Based Dosing of TXA Dose A and TXA Dose B', '32', '8', 'Study Flow Chart', '33', '9', 'Outcome Determination', '34', '10', 'Block Randomization', '38', '11', 'Informed Consent Procedures', '45', 'TIC-TOC Trial Protocol Version 2.03', 'Protocol Version Date: October 24, 2018', 'The EMSC Pediatric Emergency Care Applied Research Network']['Page 8 of 74', 'Protocol 036 (Nishijima, Kuppermann)', '12', 'Parent/guardian present and reasonable time to obtain informed consent', '46', '13', 'Parent/guardian absent or unable to provide informed consent', '48', '14', 'Parent/guardian present but not sufficient time to obtain informed consent', '49', '15', 'Mortality by time to treatment', '52', '16', 'Effect of 1 hour delay in start of treatment with TXA on proportion of', 'patients who will benefit and on risk of death', '53', 'TIC-TOC Trial Protocol Version 2.03', 'Protocol Version Date: October 24, 2018', 'The EMSC Pediatric Emergency Care Applied Research Network']['Protocol 036 (Nishijima, Kuppermann)', 'Page 9 of 74', '1 Study Summary', 'This study is a Phase II, multi-center, randomized, double-blinded, placebo-controlled', 'trial. It is a parallel arms design pilot trial randomizing 40 subjects.', '1.1 Study Objectives', 'The primary objective of this pilot study is to collect preliminary data on the safety and', 'efficacy of TXA in severely injured children. We will also assess the overall feasibility', 'to potentially conduct a large, multi-center, clinical trial evaluating the benefit of TXA', 'in children with significant hemorrhagic injuries. We will randomize subjects to one of', 'three arms: 1) TXA dose A (low), 2) TXA dose B (high), or 3) placebo. (Figure 1 on the', 'following page).', 'Specifically, the study objectives of this pilot and feasibility study are to:', 'Provide preliminary data on the safety and efficacy of TXA in severely injured', 'children with torso and/or head injuries;', 'Evaluate the ability to efficiently screen, identify, consent, randomize, and initiate', 'study intervention within 3 hours of injury;', 'Demonstrate the ability to measure and complete 48-hour (blood product transfusion', 'requirements) and early and long-term (global neurocognitive functioning) outcomes;', 'Evaluate the proportion of subjects with the outcomes of interest with the current', 'inclusion/exclusion criteria;', 'Assess protocol adherence and variability of care in randomized subjects; and', 'Identify operational efficiencies and inefficiencies with the potential to enhance the', 'success of the subsequent clinical trial', '1.2 Outcome Measures', 'This pilot study is not powered for a confirmatory test of efficacy or safety of TXA. To', 'provide preliminary data on safety and efficacy and to evaluate our ability to reliably', 'determine clinical outcomes, we will collect the following data in this pilot trial:', '1. The total amount of blood products transfused (packed red blood cells, plasma,', 'platelets, and cryoprecipitate in mL/kg) in the initial 48 hours following randomiza-', 'tion,', 'TIC-TOC Trial Protocol Version 2.03', 'Protocol Version Date: October 24, 2018', 'The EMSC Pediatric Emergency Care Applied Research Network']\n\n###\n\n", "completion": "END"}